Mutant huntingtin impairs neurodevelopment in human brain organoids through CHCHD2-mediated neurometabolic failure
-
Published:2024-08-22
Issue:1
Volume:15
Page:
-
ISSN:2041-1723
-
Container-title:Nature Communications
-
language:en
-
Short-container-title:Nat Commun
Author:
Lisowski Pawel, Lickfett SeleneORCID, Rybak-Wolf AgnieszkaORCID, Menacho CarmenORCID, Le StephanieORCID, Pentimalli Tancredi MassimoORCID, Notopoulou Sofia, Dykstra Werner, Oehler DanielORCID, López-Calcerrada Sandra, Mlody Barbara, Otto MaximilianORCID, Wu Haijia, Richter Yasmin, Roth Philipp, Anand RuchikaORCID, Kulka Linda A. M.ORCID, Meierhofer DavidORCID, Glazar Petar, Legnini Ivano, Telugu Narasimha Swamy, Hahn Tobias, Neuendorf Nancy, Miller Duncan C., Böddrich Annett, Polzin Amin, Mayatepek ErtanORCID, Diecke SebastianORCID, Olzscha HeidiORCID, Kirstein JanineORCID, Ugalde CristinaORCID, Petrakis SpyrosORCID, Cambridge Sidney, Rajewsky NikolausORCID, Kühn RalfORCID, Wanker Erich E.ORCID, Priller JosefORCID, Metzger Jakob J.ORCID, Prigione AlessandroORCID
Abstract
AbstractExpansion of the glutamine tract (poly-Q) in the protein huntingtin (HTT) causes the neurodegenerative disorder Huntington’s disease (HD). Emerging evidence suggests that mutant HTT (mHTT) disrupts brain development. To gain mechanistic insights into the neurodevelopmental impact of human mHTT, we engineered male induced pluripotent stem cells to introduce a biallelic or monoallelic mutant 70Q expansion or to remove the poly-Q tract of HTT. The introduction of a 70Q mutation caused aberrant development of cerebral organoids with loss of neural progenitor organization. The early neurodevelopmental signature of mHTT highlighted the dysregulation of the protein coiled-coil-helix-coiled-coil-helix domain containing 2 (CHCHD2), a transcription factor involved in mitochondrial integrated stress response. CHCHD2 repression was associated with abnormal mitochondrial morpho-dynamics that was reverted upon overexpression of CHCHD2. Removing the poly-Q tract from HTT normalized CHCHD2 levels and corrected key mitochondrial defects. Hence, mHTT-mediated disruption of human neurodevelopment is paralleled by aberrant neurometabolic programming mediated by dysregulation of CHCHD2, which could then serve as an early interventional target for HD.
Publisher
Springer Science and Business Media LLC
Reference141 articles.
1. Ross, C. A. & Tabrizi, S. J. Huntington’s disease: from molecular pathogenesis to clinical treatment. Lancet Neurol. 10, 83–98 (2011). 2. Arrasate, M. & Finkbeiner, S. Protein aggregates in Huntington’s disease. Exp. Neurol. 238, 1–11 (2012). 3. Bhide, P. G. et al. Expression of normal and mutant Huntingtin in the developing brain. J. Neurosci. 16, 5523–5535 (1996). 4. Nasir, J. et al. Targeted disruption of the Huntington’s disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes. Cell 81, 811–823 (1995). 5. Duyao, M. P. et al. Inactivation of the mouse Huntington’s disease gene homolog Hdh. Science 269, 407–410 (1995).
|
|